We included 78 subjects. Two subjects were
removed from the study after randomization: one
turned out to have concealed his primary substance
abuse in the first interview,the other one was
assigned to the control condition,but erroneously
received the experimental treatment. Thus,the final
sample size was 76 patients of whom 37 were
included in the experimental condition and 39 in
the control condition. This study aims at a followup
about 9 as well as 18 months later with respect
to symptomatology,functioning and quality of life
as primary outcome. Seven patients (9%) were lost
at the 9-months follow-up (one died of natural
causes),and another six patients (8%) at the
18-month follow-up,so eventually 63 patients
(83%) completed all three waves: 84% in the
experimental condition and 82% in the control
condition. All analyses are based on these patients.
Drop-outs did not differ significantly on any of the
relevant baseline variables.